Boston Herald
Boston news, sports, politics, opinion, entertainment, weather and obituaries
Related Articles
Yi Z. (@yz) on X
Curious ML/DL hacker. Love cats, daydreaming, chatting with AI, and pondering over all things logical. Meta; ex: Stakefish, Twitter, Google, CMU, Bowdoin.
Annual Meeting – ASCO
location_on McCormick Place, Chicago, IL & Online The excitement is building for #ASCO25! Preview the more than 5,000 abstracts that will be presented or published…
Yi Z. (@yz) on X
Curious ML/DL hacker. Love cats, daydreaming, chatting with AI, and pondering over all things logical. Meta; ex: Stakefish, Twitter, Google, CMU, Bowdoin.
RCC Treatment Innovations in Practice: Preparing for Individualized Patient Care
See the latest #RenalCellCarcinoma live event from @PeerView @montypal #ASCO25 #MedEd
Yi Z. (@yz) on X
Curious ML/DL hacker. Love cats, daydreaming, chatting with AI, and pondering over all things logical. Meta; ex: Stakefish, Twitter, Google, CMU, Bowdoin.
Article Archives
LOS ANGELES, Calif., April 8, 2025 – The Prostate Cancer Foundation (PCF) today announced the appointment of Phillip Koo, M.D., as chief medical officer. Dr.…
Article Archives
LOS ANGELES, Calif., April 8, 2025 – The Prostate Cancer Foundation (PCF) today announced the appointment of Phillip Koo, M.D., as chief medical officer. Dr.…
Yi Z. (@yz) on X
Curious ML/DL hacker. Love cats, daydreaming, chatting with AI, and pondering over all things logical. Meta; ex: Stakefish, Twitter, Google, CMU, Bowdoin.
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study
AbstractBackground. The phase III TIVO-3 study demonstrated improvement in progression-free survival (PFS) with tivozanib compared with sorafenib in patien
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review | JCO Precision Oncology
PURPOSEAberrant expression of nectin-4 (N4) has been observed in several malignancies emerging as new target for antibody-drug conjugates, especially in urothelial carcinoma of the bladder…